Home·Stocks·AXSM
Axsome Therapeutics, Inc

AXSM

XNAS

Axsome Therapeutics, Inc

Basic Materials · Pharmaceutical Preparations

$202.26
-4.27 (-2.07%)
15-min delayed

Drag to pan · Scroll to zoom · Hover for OHLC

Snapshot
Loading metrics…
About Axsome Therapeutics, Inc

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Employees
925
Country
US
IPO Date
2015-11-19
www.axsome.com →
Recent News
Axsome: Q1 Earnings Snapshot
Finnhub · 4h ago
Axsome Therapeutics : First Quarter 2026 Corporate Presentation
Finnhub · 4h ago
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Finnhub · 4h ago
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease Transcript
SeekingAlpha · 2d ago
Axsome Therapeutics, Inc. (AXSM) Discusses Approval of AUVELITY for Agitation Associated With Dementia Due to Alzheimer's Disease - Slideshow
SeekingAlpha · 2d ago
Needham Maintains Buy on Axsome Therapeutics, Raises Price Target to $255
Benzinga · 2d ago
Transcript : Axsome Therapeutics, Inc. - Special Call
Finnhub · 3d ago
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression
Benzinga · 3d ago
Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…
Ask AI about AXSMBuild basket with AXSMScreener

Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.